Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck

Phase 1, open-label trial in head and neck cancer (HNC) (2 cohorts), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given as a boost in combination with cisplatin and intensity modulated radiation therapy (IMRT) at 1 year and Maximum tolerated dose of stereotactic body radiotherapy treatment (SBRT) when given for disease metastatic to the head and neck at 1 year. Started Nov 2015; status: active, not recruiting.